Urologic Cancers News
Findings may inform treatment decisions after nephrectomy with positive surgical margins.
The median survival for patients with metastatic bladder cancer is increasing, possibly due to increasing use of immunotherapy.
The rising cost of care is having a negative impact on patients with bladder cancer, but a value-based approach to care might provide some relief.
Change in subcutaneous fat after initiation of immune checkpoint inhibitors may distinguish which patients will and will not respond to therapy.
Patients undergoing radical cystectomy for bladder cancer have an increased risk of thromboembolic events that may persist for months after surgery.
Partial vs radical cytoreductive nephrectomy for clear cell metastatic renal cell carcinoma was associated with a 54% decreased risk for other-cause mortality.
Total hospital costs related to radical cystectomy are higher in the West than in all other regions of the United States, a study suggests.
Lenvatinib plus pembrolizumab improved outcomes vs sunitinib in patients with advanced renal cell carcinoma.
Investigators concluded that pN1 RCC could be stratified into pN1 and pN2, with pN2 conferring a poor prognosis comparable to that of non-metastatic stage IV pN0 disease.
Aortic calcification may lead to arterial degradation that increases the risk for acute kidney injury, according to investigators.
A new study suggests that fluoroquinolones — but not other antibiotics — may reduce the efficacy of certain ICIs in certain cancers.
Researchers have characterized common adverse reactions to combination lenvatinib and pembrolizumab in patients with advanced renal cell carcinoma.
Gemcitabine plus docetaxel “may serve as a reasonable alternative first-line therapy for patients with high-risk NMIBC during the ongoing BCG shortage,” according to researchers.
Many cancer patients may be treated with drugs that were granted accelerated approval but do not provide a clinical benefit, a study suggests.
A protocol for eliminating routine opioid prescription after major urologic cancer surgery was both safe and successful, according to researchers.
A novel imaging technique, 89Zr-DFO-girentuximab PET/CT, can accurately and noninvasively identify clear cell renal cell carcinoma, a study suggests.
Cabozantinib can produce responses in patients with advanced clear cell RCC whose disease progressed on first-line checkpoint inhibitor-based therapy, a phase 2 study suggests.
Pembrolizumab demonstrated antitumor activity in patients with high-risk, papillary NMIBC who did not undergo radical cystectomy and did not respond to BCG.
Sacituzumab govitecan has demonstrated activity in patients with platinum-ineligible metastatic urothelial carcinoma whose disease progressed after checkpoint inhibitor therapy.
A high pretreatment neutrophil-to-lymphocyte ratio is associated with worse outcomes in patients with muscle-invasive bladder cancer, a study suggests.